Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Non-Small Cell Lung Cancer
DRUG: M1774|DRUG: Cemiplimab
Phase 1b/Phase 2a: Confirmed Overall response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 As assessed by Investigator, Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months|Phase 1b: Number of Participants With Adverse Events (AEs) and Treatment-related AEs, Time from randomization to final assessment at end of safety follow-up visit approximately up to 3 years and 2 months
Phase 1b/Phase 2a: Duration of Response (DoR) According to RECIST 1.1 as Assessed by the Investigator, Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months|Phase 1b/Phase 2a: Progression Free Survival (PFS) According to RECIST 1.1 as Assessed by the Investigator, Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months|Phase 1b/Phase 2a: Overall survival (OS), Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months|Phase 2a: Number of Participants With AEs and Treatment-related AEs, Time from randomization to final assessment at end of safety follow-up visit (approximately up to 3 years and 2 months)
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..